Clinical Trials Browser

Phase 3 × INDUSTRY × XL647 × Clear all

NCT01487174 2022-05-13

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung